Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries, and the company was founded in 1984. The company was initially formed as a Partnership Firm as Anupam Rasayan effective from April 01, 1984, at Surat in Gujarat, and was registered under the Indian Partnership Act 1932 with Registrar of Firms Surat in October 22, 1984. Its date of incorporation as a joint stock company is September 30, 2003.
Anupam Rasayan India Ltd. is an India-based company, which is engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals. The company has established itself as a prominent player in the Indian specialty chemicals sector with a focus on life science-related products and other specialty chemicals.
The Company's segments include Life Science related Specialty Chemicals and Other Specialty Chemicals. The Life Science related Specialty Chemicals segment includes agrochemicals (including crop protection), personal care, and pharmaceuticals businesses.
The Life Science Specialty Chemicals segment constitutes 91% of business in FY24, with:
- Agrochemicals (65%) manufacturing agro intermediates and agro active ingredients (insecticides, fungicides, and herbicides) for the agrochemical industry.
- Personal Care (17%) manufacturing antibacterial and ultraviolet protection intermediates and ingredients for the personal care industry.
- Pharmaceuticals (9%) focusing on developing intermediates and 'key starting materials' for active pharmaceutical ingredients.
The pharmaceutical segment's revenue share grew from 4% in FY23 to 9% in FY24, and the company anticipates further growth in double digits in the coming year.
The Other Specialty Chemicals segment includes specialty pigments, specialty dyes, and polymer additives.
The company has six manufacturing facilities across Gujarat, all equipped with sophisticated Machineries and certified with ISO 9001:2015 and ISO 14001:2015, and cater to customers in both domestic and international markets. Anupam Rasayan India Ltd. has six manufacturing units in India with over 1350 committed employees. The organization's workforce consists of electrical, mechanical, and chemical engineers, PhDs, science graduates, and qualified safety workers and officers.
The company has a DSIR recognized R&D center headed by Dr. Nileshkumar Naik along with a team of 55 professionals.
Consolidated revenue for the quarter Q4 FY25 stood at ₹506 Crore, registering a growth of 22% YoY and 31% QoQ. EBITDA (incl. other income) was at ₹150 Crore in Q4 FY25 as compared to ₹104.7 Crore in Q4 FY24, up 43% and this would translate into 30% EBITDA margin in this quarter. Profit After Tax was at ₹62.9 Crore in Q4 FY25 as compared to ₹40.5 Crore in Q4 FY24; up 56% YoY.
Consolidated revenue for the full year FY25 stood at ₹1,448 Crore, registering a degrowth of 4% YoY. Profit After Tax was at ₹160 Crore in FY25 as compared to ₹167.4 Crore in FY24.
Anupam Rasayan India Ltd has a market capitalization of ₹12,375 Crore as on June 12, 2025. As per Value Research classification, it is a Small Cap company. The P/B ratio of Anupam Rasayan India Ltd is 4.34 times as on June 12, 2025, a 34% premium to its peers' median range of 3.23 times. The P/E ratio of Anupam Rasayan India Ltd is 132.57 times as on June 12, 2025, a 256% premium to its peers' median range of 37.23 times.
The chairman of the company is Kiran Chhotubhai Patel, and the managing director is Anand Sureshbhai Desai. Promoter holding in Anupam Rasayan India Ltd has gone down to 61.18% as of March 2025 from 61.23% as of June 2024.
The company is listed on the Bombay Stock Exchange (BSE) with the code 543275 and the National Stock Exchange (NSE) with the code ANURAS.
On June 12, 2025, Anupam Rasayan signed a 3-year Master Purchase Agreement with a Japanese multinational for specialty chemicals. The company's performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac.
Amidst the evolving landscape, Anupam Rasayan has strategically positioned itself to capitalize on opportunities while maintaining commitment to sustainability. The company emphasizes the need for decarbonization and collectively works towards the goal of net-zero emissions.
While H1 FY25 was subdued due to weak macro conditions, the company has shown clear signs of recovery particularly in Q4 FY25 where meaningful improvement was seen with sales increasing both year-on-year and sequentially. The company remains confident in its ability to return to the historical growth rates achieved prior to the recent slowdown.
The company's Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to revenue. Both segments, coupled with strong performance of Tanfac, led to significant growth in Q3 FY25, fueling a robust 31% QoQ revenue growth on a consolidated basis. For the full year, they expect these segments to play a substantial role in overall revenue, with this upward trend projected to continue into FY26.
